AEON - AEON Biopharma Inc. - Ordinary Shares - Class A
Close
0.8335
-0.115 -13.797%
Share volume: 335,809
Last Updated: Fri 30 Aug 2024 10:00:00 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$0.95
-0.12
-12.12%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
-14.30%
1 Month
-57.26%
3 Months
-42.12%
6 Months
-92.99%
1 Year
-85.43%
2 Year
-91.51%
Key data
Stock price
$0.83
DAY RANGE
$0.80 - $0.93
52 WEEK RANGE
$0.80 - $17.17
52 WEEK CHANGE
-$0.84
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO:
Region: US
Website:
Employees: 3
IPO year: -
Issue type: Common Stock
Market: NYSE American
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website:
Employees: 3
IPO year: -
Issue type: Common Stock
Market: NYSE American
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
we are a nasdaq-listed special purpose acquisition company whose business purpose is to effect a merger or similar business combination with one or more businesses. our acquisition strategy is to identify and complete our initial business combination with a medical technology company in the healthcare industry. our sponsor team consists of chairman/ceo robert palmisano, president vikram malik, cfo oleg grodnensky and chief legal officer david meredith.
Recent news